搜尋結果
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
CNBC· 15 小時前The Food and Drug Administration on Friday expanded the approval of GSK's respiratory ...
Health Care Roundup: Market Talk
The Wall Street Journal· 21 小時前Find insights on Biomea Fusion, Eli Lilly, Bayer, and more in the latest Market Talks covering ...
efficacy 相關
廣告